Dosing and uses of Piracetam, dinagen, myocalm, nootropil, qropi
Adult dosage forms and strengths
1.6-9.6 g/day PO
Pediatric dosage forms and strengths
<16 years old: not recommended
Suggested uses of Piracetam, dinagen, myocalm, nootropil, qropi
Alzheimers disease, dementia, memory dysfunction, alcoholism, Raynaud's phenomenon, DVT, stroke, tardive dyskinesia, dyslexia, brain injury, vertigo
Efficacy
Approved in many European countries for myoclonus, aging-related conditions (dementia, Alzheimer's)
Some clinical studies show efficacy in dyslexia, brain injury, vertigo
Piracetam, dinagen, myocalm, nootropil, qropi adverse (side) effects
Frequency not defined
diarrhea, weight gain, somnolence, insomnia, nervousness, depression, hyperkinesia, rash
Warnings
Contraindications
Hepatic impairment
Severe renal impairment
Pregnancy, lactation
Hemorrhagic diathesis
Cautions
Avoid abrupt withdrawaL
Elderly
Renal impairment
May impair ability to drive or perform hazardous tasks
Blood dyscrasias
Pregnancy and lactation
Pregnancy category: contraindicated
Lactation: contraindicated
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Piracetam, dinagen, myocalm, nootropil, qropi
Peak Plasma Time: 1.5 hr
Half-Life: 5 hr
Bioavailability: ~100%
Metabolism: no identified metabolites
Excretion: urine
Mechanism of action
Unknown, GABA analog
